ResMed (RMD) Stock Forecast & Price Target

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

• ResMed Inc. recently received an upgrade to an Outperform rating from RBC Capital Markets, which raised its price target to $262, signaling strong confidence in the company's ability to achieve high-single-digit earnings per share growth over the next three years despite current market conditions.
• The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $2.95, which exceeded the consensus estimate of $2.89, while also achieving a net margin of 26.94% and a return on equity of 25.58%, indicating efficient capital management and profitability.
• ResMed Inc. is currently trading at $225.35, which is below the consensus price target of $241.69, suggesting potential upside for investors as the stock remains undervalued relative to analyst expectations and its recent 50-day simple moving average of $218.95.
• Institutional interest in the stock has increased significantly, with major investors such as Bank of America Corp DE and Nykredit A S establishing new positions worth over $151 million and $66 million respectively during the second quarter, reflecting broader market confidence in the company's long-term growth prospects.
• The company recently increased its quarterly dividend to $0.66 per share, representing a boost from the previous $0.60, which provides a dividend yield of approximately 1.16% and demonstrates a commitment to returning value to shareholders while maintaining a sustainable payout ratio of 25.31%.